Equity Profile

LEGN

Legend Biotech Corporation

Health CareBiotechnology$5.0B

Dec1Thu

Pre-Earnings Brief

UpcomingQ1-2026After Close5:00 PM EST

Company Snapshot

Legend Biotech Corporation is a biotechnology company focused on developing innovative cell therapies for cancer treatment. Operating in the health care sector, its advancements in this field are significant as they aim to provide new solutions for patients with serious diseases.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its therapies.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

LEGN Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 6Q

EPS Beat Streak

EPS Beat Rate

67%

Avg EPS Surprise

+12.73%

Avg Stock Reaction

+3.44%

Last Quarter Recap

In the last quarter, Legend Biotech reported an EPS of -$0.16, which was better than the expected -$0.29, indicating a positive surprise. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, the market is cautiously optimistic about Legend Biotech's upcoming earnings, especially given its history of beating EPS estimates. Investors are looking for signs of growth in revenue and advancements in product development.

Bull Case

If Legend Biotech can demonstrate strong revenue growth and continued success in clinical trials, it could validate the company's innovative approach and drive the stock price higher.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing updates on its therapies, it could lead to a decline in investor confidence and a drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for this quarter?

Given the company's history of EPS surprises, this figure will be crucial in determining market sentiment and stock movement.

What updates will be provided on product development and clinical trials?

Investors are keen to know about the progress of therapies, as this could significantly impact future revenue and growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Legend Biotech's therapies to gain traction in the market, especially given the recent positive surprise in EPS.

Supporting Evidence

The company's history of beating EPS estimates suggests it may continue to outperform expectations.

Options pricing indicates a lower expected move compared to historical averages, suggesting potential undervaluation of volatility.

Key Risk

If the company reports an EPS significantly better than expected, it could challenge current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis this quarter revolves around the company's ability to manage costs while advancing its innovative therapies.

Bull Confirmed If

An EPS above -$0.10 would confirm the bull case, indicating better-than-expected cost management and operational efficiency.

Bear Confirmed If

An EPS below -$0.30 would confirm the bear case, suggesting ongoing challenges in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±5%

Historical Avg

±6.1%

Pricing cheap

The options market is pricing in a 5% move, suggesting that traders expect some volatility around the earnings report.

Options are pricing ±5.0% while LEGN has averaged ±6.1% over the last 6 prints — setup is pricing cheap.

Detail

30d HV

72.4%

Calls (40K)P/C Ratio: 0.32Puts (11K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options pricing cheap in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Legend Biotech beats expectations, history suggests the stock could rise by around 1.71% on the first day post-earnings.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity on future guidance.

Miss

If the company misses expectations, history suggests a potential decline of around 6.91% on the first day post-earnings.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the timeline for clinical trial results.
2Details on cash burn and how it aligns with future funding needs.
3Insights into competitive positioning in the biotechnology sector.
4Management's outlook on market demand for its therapies.
5Any changes in strategic partnerships or collaborations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Elbit Systems Ltd.

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its therapies.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

LEGN Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 6Q

EPS Beat Streak

EPS Beat Rate

67%

Avg EPS Surprise

+12.73%

Avg Stock Reaction

+3.44%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Legend Biotech can demonstrate strong revenue growth and continued success in clinical trials, it could validate the company's innovative approach and drive the stock price higher.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing updates on its therapies, it could lead to a decline in investor confidence and a drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for this quarter?

Given the company's history of EPS surprises, this figure will be crucial in determining market sentiment and stock movement.

What updates will be provided on product development and clinical trials?

Investors are keen to know about the progress of therapies, as this could significantly impact future revenue and growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Legend Biotech's therapies to gain traction in the market, especially given the recent positive surprise in EPS.

Supporting Evidence

The company's history of beating EPS estimates suggests it may continue to outperform expectations.

Options pricing indicates a lower expected move compared to historical averages, suggesting potential undervaluation of volatility.

Key Risk

If the company reports an EPS significantly better than expected, it could challenge current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis this quarter revolves around the company's ability to manage costs while advancing its innovative therapies.

Bull Confirmed If

An EPS above -$0.10 would confirm the bull case, indicating better-than-expected cost management and operational efficiency.

Bear Confirmed If

An EPS below -$0.30 would confirm the bear case, suggesting ongoing challenges in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±5%

Historical Avg

±6.1%

Pricing cheap

The options market is pricing in a 5% move, suggesting that traders expect some volatility around the earnings report.

Options are pricing ±5.0% while LEGN has averaged ±6.1% over the last 6 prints — setup is pricing cheap.

Detail

30d HV

72.4%

Calls (40K)P/C Ratio: 0.32Puts (11K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options pricing cheap in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Legend Biotech beats expectations, history suggests the stock could rise by around 1.71% on the first day post-earnings.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity on future guidance.

Miss

If the company misses expectations, history suggests a potential decline of around 6.91% on the first day post-earnings.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the timeline for clinical trial results.
2Details on cash burn and how it aligns with future funding needs.
3Insights into competitive positioning in the biotechnology sector.
4Management's outlook on market demand for its therapies.
5Any changes in strategic partnerships or collaborations.